MEDICUS PHARMA LTD. Stock-Based Compensation
MEDICUS PHARMA LTD. (MDCX) reported Stock-Based Compensation of $2.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-12
- MEDICUS PHARMA LTD. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.41M, a 1096.98% increase year-over-year.
- MEDICUS PHARMA LTD. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $599.31K, a 433.77% increase year-over-year.
- MEDICUS PHARMA LTD. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $429.71K, a 368.48% increase year-over-year.
- MEDICUS PHARMA LTD. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $852.76K.
- MEDICUS PHARMA LTD. share-based payment arrangement, noncash expense for fiscal 2025 was $1.51M, a 112.05% increase from fiscal 2024.
- MEDICUS PHARMA LTD. share-based payment arrangement, noncash expense for fiscal 2024 was $713.12K, a 623.35% increase from fiscal 2023.
- MEDICUS PHARMA LTD. share-based payment arrangement, noncash expense for fiscal 2023 was $98.58K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.01M 10-Q · filed 2026-08-12 | $2.43M derived: sum of 3 quarters · filed 2026-08-12 | $3.29M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $599.31K 10-Q · filed 2026-05-14 | $1.03M derived: sum of 2 quarters · filed 2026-05-14 | $1.88M derived: sum of 3 quarters · filed 2026-05-14 | $2.00M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $429.71K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $1.28M derived: sum of 2 quarters · filed 2026-03-25 | $1.40M derived: sum of 3 quarters · filed 2026-08-12 | $1.51M 10-K · filed 2026-03-25 |
| 2025-09-30 | $852.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $970.21K derived: sum of 2 quarters · filed 2026-08-12 | $1.08M 10-Q · filed 2025-11-14 | $1.17M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $117.45K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $229.72K 10-Q · filed 2026-08-12 | $321.45K derived: sum of 3 quarters · filed 2026-08-12 | $321.45K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $112.28K 10-Q · filed 2026-05-14 | $204.00K derived: sum of 2 quarters · filed 2026-05-14 | $204.00K derived: sum of 3 quarters · filed 2026-05-14 | $789.44K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $91.72K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $91.72K derived: sum of 2 quarters · filed 2026-03-25 | $677.17K derived: sum of 3 quarters · filed 2026-03-25 | $713.12K 10-K · filed 2026-03-25 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $585.44K derived: sum of 2 quarters · filed 2025-11-14 | $621.39K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $585.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $621.39K 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $35.95K 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $98.58K 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |